GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) Short Interest Down 25.7% in May

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Get Free Report) was the recipient of a significant decline in short interest in May. As of May 31st, there was short interest totalling 38,100 shares, a decline of 25.7% from the May 15th total of 51,300 shares. Currently, 0.1% of the company's stock are short sold. Based on an average daily volume of 12,100 shares, the short-interest ratio is presently 3.1 days.

GENFIT Stock Down 0.8%

NASDAQ:GNFT opened at $4.12 on Wednesday. GENFIT has a 1 year low of $2.55 and a 1 year high of $6.42. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.08. The stock has a 50-day simple moving average of $4.04 and a 200-day simple moving average of $3.80.

Institutional Investors Weigh In On GENFIT

A hedge fund recently bought a new stake in GENFIT stock. Millennium Management LLC acquired a new position in shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of GENFIT as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 2.24% of the company's stock.

About GENFIT

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.